A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic NSCLC

Trial Identifier: D7020C00001
Sponsor: AstraZeneca
Start Date: September 2021
Primary Completion Date: August 2026
Study Completion Date: March 2028
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, 3000
BE Anderlecht, BE, 1070
BE Leuven, BE, 3000
BR Florianópolis, BR, 88034-000
BR Natal, BR, 59075-740
BR Porto Alegre, BR, 90035903
BR Rio de Janeiro, BR, 20231-050
BR Sao Paulo, BR, 01246-000
CN Chengdu, CN, 610041
CN Chongqing, CN, 400030
DK Copenhagen, DK, 2100
ES Barcelona, ES, 08035
ES Madrid, ES, 28027
ES Madrid, ES, 28041
FR Dijon, FR, 21079
FR Toulouse, FR, 31059
GE Tbilisi, GE, 0112
JP Kashiwa, JP, 227-8577
JP Niigata-shi, JP, 951-8566
JP Sendai-shi, JP, 981-0914
JP Tokyo, JP, 104-0045
KR Seoul, KR, 05505
KR Seoul, KR, 03722
KR Seoul, KR, 03082
MD Chisinau, MD, MD-2025
MY Kuala Lumpur, MY, 59100
MY Kuching, MY, 93586
NL Groningen, NL, 9713 GZ
NL LEIDEN, NL, 2333 ZA
NL UTRECHT, NL, 3584 CX
TH Bangkok, TH, 10700
TH Muang, TH, 50200
TH Mueang Chanthaburi, TH, 22000
TW Taichung, TW
TW Taichung, TW, 40201
TW Tainan City, TW, 70403
TW Taipei City, TW, 110
US, IL Chicago, IL, US, 60637
US, MN Rochester, MN, US, 55905
US, VA Fairfax, VA, US, 22031